Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin
- Sang Mok Yeo; Hayeon Park; Jin Hyuk Paek; Woo Yeong Park; Seungyeup Han; Sung Bae Park; Kyubok Jin
- Dept. of Internal Medicine (내과학)
- Issue Date
- Medicine (Baltimore)., Vol.98(3) : e14150-e14150, 2019
Dapagliflozin (a sodium-glucose cotransporter-2 [SGLT2] inhibitor) represents the most recently approved class of oral medications for the treatment of type 2 diabetes. Dapagliflozin lowers plasma glucose concentration by inhibiting the renal reuptake of glucose in the proximal renal tubules. In 2015, the US Food and Drug Administration released a warning concerning a potential increased risk of ketoacidosis in patients taking this medication.
We present the case of a 23-year-old woman with type 2 diabetes treated with dapagliflozin (10mg, once a day) for 2 years who presented to the emergency department with abdominal pain.
We diagnosed her with severe ketoacidosis with a normal glucose level (177 mg/dL) due to dapagliflozin, accompanying acute pancreatitis due to hypertriglyceridemia. We concluded that the precipitating factor for euglycemic ketoacidosis was pseudomembranous colitis.
She was treated with intravenous infusions of insulin, isotonic saline, and sodium bicarbonate as diabetic ketoacidosis treatment.
She was in shock with severe metabolic acidosis. After continuous renal replacement therapy, the uncontrolled metabolic ketoacidosis was treated, and she is currently under follow-up while receiving metformin (500mg, once a day) and shortand long-acting insulins (8 units 3 times and 20 units once a day).
We report an unusual case of SGLT2 inhibitor-induced euglycemic ketoacidosis recovered by continuous renal replacement therapy in a patient with type 2 diabetes and recurrent acute pancreatitis due to hypertriglyceridemia. We diagnosed a rare complication of the SGLT2 inhibitor in a patient with type 2 diabetes in whom uncontrolled metabolic ketoacidosis could be effectively managed via continuous renal replacement therapy.
- dapagliflozin; ketoacidosis; renal replacement therapy; SGLT2 inhibitor
- Appears in Collections:
- 1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
- Keimyung Author(s)
- 백진혁; 박우영; 한승엽; 박성배; 진규복
- Full Text
- File in this Item
- oak-2019-0036.pdf(205.83 kB)Download
- RIS (EndNote)
- XLS (Excel)